Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that ISP Chile had conducted an inspection at the Company's manufacturing facility located at Daman, India from 28th March, 2022 to 01st April, 2022. At the end of the inspection, no observations critical to Good Manufacturing Practices were detected. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Closure of Trading Window
This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 30th March, 2022 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and year ended 31st March, 2022 are communicated to the Stock Exchanges. Buy Alkem; target of Rs 3870 : Motilal Oswal
Motilal Oswal is bullish on Alkem recommended buy rating on the stock with a target price of Rs 3870 in its research report dated March 07, 2022. Alkem Laboratories Ltd - 539523 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Alkem Laboratories Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Alkem Laboratories Ltd - 539523 - Postal Ballot- Details Of The Voting Results Of The Postal Ballot Through Remote E-Voting - Regulation 44(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
In continuation of our letter dated 11th January, 2022 and pursuant to provisions of Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the resolution as proposed in the Postal Ballot Notice dated 20th December, 2021 has been passed by the Members of the Company with requisite majority. We are enclosing herewith the details regarding the voting results of the business transacted through Postal Ballot by remote e-voting process in the prescribed format alongwith the Scrutinizer's Report. The same are also being uploaded on Company's website viz. https://www.alkemlabs.com/. The approval is deemed to have been received on the last date of remote e-voting, i.e. 10th February, 2022. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to intimate you that Alkem Laboratories Limited (the 'Company') and Harvard University's Office of Technology Department (OTD) have signed a license agreement for the development and commercialization of a novel technology for effective treatment of diabetic neuropathy, foot ulcers, peripheral arterial disease (PAD), and other injuries caused by vascular disease. A press release in this regard is enclosed herewith. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find enclosed herewith the transcript of the 'Q3 FY2022 Earnings Conference Call' which was hosted by the Company on Friday, 04th February, 2022. The said transcript shall also be made available on the website of the Company. Kindly take the same on record.
Earnings Call for Q3FY22 Alkem Laboratories Ltd.
Conference Call with Alkem Laboratories Ltd. Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript. 